[A clinical trial of neoadjuvant intraarterial chemotherapy for the treatment of locally advanced breast cancer].
Seventeen patients with advanced breast cancer were treated with neoadjuvant intraarterial chemotherapy with high dose epirubicin. The following results were obtained. 1. Excellent down-staging effect (tumor reduction > 50% of its original size: 82.4%) was confirmed on primary lesions. In addition, an objective response rate of 37.5% was observed at the metastatic sites. 2. Leukopenia, which was the dose-limiting factor in this regimen, appeared at the frequency of 82.4%. Therefore, we needed G-CSF and/or a sufficient interval between each cycle. 3. A great number of cases and sufficient follow-up period will be indispensable to discuss survival in future investigation.
Takatsuka
Y
Y
Dept. of Surgery, Kansai Rosai Hospital.
Shin
E
E
Kikkawa
N
N
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D015996:Survival Rate
D000903:Antibiotics, Antineoplastic; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin